Biomarkers for human monocyte myeloid-derived suppresor cells
US10288619B2 · kind B2 · utility
0Cited by
0References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 24, 2015 |
| Grant date | May 14, 2019 |
| Priority date | — |
| Expiry date | Jun 24, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/50
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A method for diagnosing an increased risk of a cancer in a subject includes the steps of obtaining a blood sample from the subject and determining, in the blood sample, a level of two or more of the polypeptides selected from the group consisting of VNN2, KCNJ15, SERPINB2, CREB5, ICAM3, NFE2, MNDA, PXN, FCAR, TSHZ3, NRG1, ALOX5AP, PAD14, PAD12, QPC, VNN1, SERPINB10, CLEC4D, TREM1, CLEC4E, CD82, MGAM, TMEM45B and VNN3, wherein an increase in the level of two or more of the polypeptides compared to a control level is indicative of an increased risk of cancer in the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.